Expansion of tumor infiltrating lymphocytes from liquid tumors and therapeutic uses thereof
AssigneeIovance Biotherapeutics, Inc.
InventorsLavakumar Karyampudi, Maria Fardis
Life of this patent
Estimating the term…
Abstract
Methods of expanding tumor infiltrating lymphocytes (TILs), including peripheral blood lymphocytes and marrow infiltrating lymphocytes, from blood and/or bone marrow of patients with hematological malignancies, such as liquid tumors, including lymphomas and leukemias, and uses of such expanded TILs in the treatment of diseases such as cancers and hematological malignancies are disclosed herein.
Claims29
-29. (canceled)
A method for expanding peripheral blood lymphocytes (PBLs) from peripheral blood of a patient who has relapsed or did not respond to a first course of treatment with ibrutinib or another insulin-like tyrosine kinase (ITK) inhibitor, the method comprising the steps of:
- (a) re-treating the patient with a second course of ibrutinib or such other ITK inhibitor;
- (b) obtaining a sample of peripheral blood mononuclear cells (PBMCs) from peripheral blood of the patient;
- (c) culturing said PBMCs in a culture comprising a first culture medium with IL-2 and anti-CD3/anti-CD28 antibodies, for a period of time selected from the group consisting of:
- about 9 days, about 10 days, about 11 days, about 12 days, about 13 days and about 14 days, thereby effecting expansion of PBLs from said PBMCs;
- and
- (d) harvesting the PBLs from the culture in step (c).
A method for treating a hematological malignancy in a patient who has relapsed or did not respond to a first course of treatment with ibrutinib or another insulin-like tyrosine kinase (ITK) inhibitor, the method comprising the steps of:
- (a) re-treating the patient with a second course of ibrutinib or such other ITK inhibitor;
- (b) obtaining a sample of peripheral blood mononuclear cells (PBMCs) from peripheral blood of the patient;
- (c) culturing said PBMCs in a culture comprising a first culture medium with IL-2 and anti-CD3/anti-CD28 antibodies, for a period of time selected from the group consisting of:
- about 9 days, about 10 days, about 11 days, about 12 days, about 13 days and about 14 days, thereby effecting expansion of peripheral blood lymphocytes (PBLs) from said PBMCs;
- (d) harvesting the PBLs from the culture in step (c);
- and
- (e) administering the PBLs to the patient in a therapeutically effective amount to treat said hematological malignancy.
Dependencies are inferred from the claim text.